Syndex was founded by Geoff Smith in 2022.

Who are Syndex's investors?

Syndex's investors include OMX Ventures, +ND Capital, ARCH Venture Partners.

How much funding has Syndex raised?

Syndex has disclosed $15.5M raised across 1 round.

Where is Syndex headquartered?

Syndex is headquartered in Santa Monica, US.

Syndex

Santa Monica, US · Founded 2022 · 3 known investors

Find your way into Syndex

Paths you didn't know you had: your email and LinkedIn already hold routes to the Syndex team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Syndex develops mcPCR (methyl copying PCR), a proprietary platform technology that amplifies DNA while preserving methylation patterns, addressing the challenge of low DNA levels in clinical samples. The technology targets clinical applications including oncology and early cancer detection, residual disease and treatment monitoring, drug development, and chronic disease detection.

Biotech Deep Tech Medical Devices

Founders & leadership

Syndex was founded in 2022 by Geoff Smith.

Geoff Smith Founder & CEOGeoff Smith led Technology Development globally at Illumina, where he was involved in developing NGS workflows including sample preparation, sequencing technology, and instrument systems. He has experience in next-generation sequencing applications spanning oncology, infectious disease detection, and other clinical domains.

Jason Betley Chief Product OfficerHe previously held VP-level positions in research and technology development at biotech companies, holds a PhD from the University of Sheffield, and completed a postdoctoral fellowship at the University of Colorado at Boulder, with expertise in chemistry, DNA sequencing, and biochemistry.

Investors · 3

OMX Ventureslisted by OMX VenturesLincolnshire

How we know: OMX Ventures's portfolio page · press coverage · the VCSheet dataset · Not right? Tell us

+ND CapitalreportedWoodside · $540K – $5.4M

How we know: press coverage · Not right? Tell us

ARCH Venture PartnersreportedChicago · $50K – $250M

How we know: a partner's Signal profile · press coverage · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$15.5M disclosed across 1 round · 2025

▶$15.5MraisedMar 2025 · 12 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Geoff Paul SmithExecutive Officer, Director

Offering amount: $15.5M
Amount sold: $15.5M
First sale: Feb 2025
Incorporated: Corporation, Delaware, 2022
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 8

Thumbnail for SyntheXSyntheX develops the ToRFLEx platform, a first-in-class drug discovery technology that enables screening for compounds that modulate protein-protein interactions and targeted protein degradation for previously inaccessible drug targets identified by geneticists. The company builds an internal oncology pipeline and partners with external organizations to expand adoption of its platform.

Syndax PharmaceuticalsSyndax Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and antibody cancer therapies, including two FDA-approved medicines: revumenib (a menin inhibitor for acute leukemias) and axatilimab (a CSF-1R blocking antibody for graft-versus-host disease and fibrotic diseases), along with clinical-stage programs exploring expanded uses and combinations in oncology.

SyenexSyenex provides cell delivery technologies and contract development services for therapeutic cell engineering, serving biopharmaceutical companies developing cell-based therapies. The company integrates cell engineering and delivery capabilities with regulatory support for clinical development.

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

SyntaxSyntax Bio develops a discovery platform that accelerates stem cell-derived therapies by using its proprietary Cellgorithm technology to control and direct cell differentiation. The platform enables biopharma companies to speed up cell therapy development, reduce manufacturing costs, and expand their pipeline of potential treatments.

Senex BiotechnologySenex Biotechnology develops cancer and chronic disease therapies by targeting aging-related biological pathways identified through functional genomics. The company focuses on oncology indications including ovarian, breast, and prostate cancers.

SOSVSOSV is a venture capital firm that provides pre-seed funding (up to $550,000) to founders in deep technology sectors including life sciences, robotics, industrial automation, energy transition, and medical technology. The firm operates accelerator programs in New York City, San Francisco, and Newark, NJ, and does not invest in enterprise software, fintech, blockchain, crypto, cybersecurity, or ecommerce.

SynlogicSynlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases. The company applies synthetic biology approaches to design programmable therapeutic candidates for patients.

Companies working in the same space as Syndex.

In the news

Syndex Bio Unveils mcPCR Technology at AGBT 2026 Following $15.5M Seed Financing — Syndex Bio | Introducing mcPCR™ Like PCR, but for methylationsyndex.bio · Feb 2026

Frequently asked questions

What does Syndex do?: Syndex develops mcPCR (methyl copying PCR), a proprietary platform technology that amplifies DNA while preserving methylation patterns, addressing the challenge of low DNA levels in clinical samples. The technology targets clinical applications including oncology and early cancer detection, residual disease and treatment monitoring, drug development, and chronic disease detection.
Who founded Syndex?: Syndex was founded by Geoff Smith in 2022.
Who are Syndex's investors?: Syndex's investors include OMX Ventures, +ND Capital, ARCH Venture Partners.
How much funding has Syndex raised?: Syndex has disclosed $15.5M raised across 1 round.
Where is Syndex headquartered?: Syndex is headquartered in Santa Monica, US.